Bad things happen to sick people. They get sicker. They end up on ventilators. They die.

These are all adverse outcomes, whether receiving leronlimab, placebo or pixie dust. This is the point of a random, double blinded, placebo controlled study.

The only ones who could know what is happening now are Patterson (who noted “interesting“ results in his analyses of patient samples. As strong an indication as one could want without someone going to jail for violating the rules) and independent review board.

Of course people are dying. We’re addressing the sick and profoundly sick Covid patients.

The point for non-bio/non-research/non-medical folks is that the sicker the patient population (the severe/critical who need leronlimab not Remdesivir / Tamiflu-for-Covid) the more challenging it is to determine whether they died because the drug is no good or due to the underlying comorbidities that contributed to their being sick (renal failure, hypertension, diabetes, obesity).

The process takes time. None of us likes it least of all Dr. Pourhassan who appears beside himself that he is not in the position yet to help those in need.

He seemed devastated when the FDA shut down EIND Covid authorization, as individuals in need for whom he was personally contacted were out of luck.

All of this (patients dying, short attacks, our agita), is Short Term. Cytodyn and some of the longs here are approaching ten years in the fight to get this to market.

We have been granted an opportunity to practice our patience.

It will all come together soon enough.